歌礼制药-B（01672.HK）今日盘中大跌5.01%，跌幅显著。这一走势与公司最新发布的2024年度业绩报告密切相关。
根据歌礼制药-B公布的2024年度业绩，公司收入录得128万元人民币，同比大幅下降97.7%。更为严峻的是，公司亏损由上一年度的1.45亿元人民币扩大至3.01亿元人民币，每股亏损达30.05分。此外，公司决定不派发末期股息。
分析人士指出，歌礼制药-B的业绩表现远低于市场预期，收入的大幅下滑和亏损的显著扩大反映出公司面临严峻的经营挑战。这些负面因素综合导致投资者信心受挫，进而引发了股价的大幅下跌。市场将密切关注公司未来的经营策略调整和业绩改善措施。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.